- « Previous
- Clinical Pharmacology
- Next »
Cefzil
Clinical Pharmacology
Cefzil
Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard cefprozil powder should provide the following MIC values:
| Microorganism | MIC (µg/mL) |
| Enterococcus faecalis ATCC 29212 | 4-16 |
| Escherichia coli ATCC 25922 | 1-4 |
| Haemophilus influenzae ATCC 49766 | 1-4 |
| Staphylococcus aureus ATCC 29213 | 0.25-1 |
| Streptococcus pneumoniae ATCC 49619 | 0.25-1 |
Diffusion Techniques: Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure3 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30 µg cefprozil to test the susceptibility of microorganisms to cefprozil.
Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30-µg cefprozil disk should be interpreted according to the following criteria:
| Zone diameter (mm) | Interpretation |
| ≥ 18 | Susceptible (S) |
| 15-17 | Intermediate (I) |
| ≤ 14 | Resistant (R) |
Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for cefprozil.
As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30-µg cefprozil disk should provide the following zone diameters in these laboratory test quality control strains.
| Microorganism | Zone diameter (mm) |
| Escherichia coli ATCC 25922 | 21-27 |
| Haemophilus influenzae ATCC 49766 | 20-27 |
| Staphylococcus aureus ATCC 25923 | 27-33 |
| Streptococcus pneumoniae ATCC 49619 | 25-32 |
Clinical Studies
Study One
In a controlled clinical study of acute otitis media performed in the United States where significant rates of β-lactamase-producing organisms were found, cefprozil was compared to an oral antimicrobial agent that contained a specific β-lactamase inhibitor. In this study, using very strict evaluability criteria and microbiologic and clinical response criteria at the 10 to 16 days post-therapy follow-up, the following presumptive bacterial eradication/clinical cure outcomes (ie, clinical success) and safety results were obtained:
U.S. Acute Otitis Media Study Cefprozil vs β-lactamase inhibitor-containing control drug
| EFFICACY: | ||
| Pathogen | % of Cases with Pathogen (n=155) |
Outcome |
| S. pneumoniae | 48.4% | cefprozil success rate 5% better than control |
| H. influenzae | 35.5% | cefprozil success rate 17% less than control |
| M. catarrhalis | 13.5% | cefprozil success rate 12% less than control |
| S. pyogenes | 2.6% | cefprozil equivalent to control |
| Overall | 100.0% | cefprozil success rate 5% less than control |
Safety
Generic Name: Cefprozil
- « Previous
- Clinical Pharmacology
- Next »
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Parenting and Pregnancy
Get tips for baby and you.
Health Extras
Overscheduled Families
Do you run your kids from one activity to another, day after day? If so, you should take a minute to watch.See more WebMD Videos »
